title: Practical Guide to Direct New Oral Anticoagulant Use for Secondary Stroke Prevention in Atrial Fibrillation.
abstract: Anticoagulation remains the optimal treatment choice for secondary stroke prevention of AF. The vitamin K antagonists (VKAs) have been the choice of treatment for the last 60 years, but the new oral anticoagulants are now a safe option for treatment of non-valvular AF (NVAF) in the right patient population, taking into account age, renal function, bleeding risk, cardiovascular comorbidities, cost, and drug interactions.
authors.affiliation: Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA. ROCHELLE.SWEIS@luhs.org.
authors.forename: Rochelle
authors.initials: R
authors.lastname: Sweis
authors.affiliation: Department of Neurology, Stritch School of Medicine, Loyola University Chicago, Chicago, IL, USA. JBILLER@lumc.edu.
authors.forename: José
authors.initials: J
authors.lastname: Biller
keywords: Atrial fibrillation; NOACs; Stroke; Vitamin K antagonists